Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
Frequently asked questions
What sector does Vivoryon Therapeutics NV (VVY) operate in?
Vivoryon Therapeutics NV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Vivoryon Therapeutics NV (VVY) current stock price?
As of the latest data, Vivoryon Therapeutics NV stock price is €1.13, with a previous close of €1.14. Vivoryon Therapeutics NV lost -€0.02 in the last trading session, representing a -1.32% loss.
What is Vivoryon Therapeutics NV (VVY) current market capitalization?
Vivoryon Therapeutics NV market cap is approximately 33.32 million.
What is Vivoryon Therapeutics NV (VVY) Earnings Per Share (EPS)?
The trailing EPS is -€0.33, and the forward EPS is -€0.31.
What is Vivoryon Therapeutics NV (VVY) EBITDA?
Vivoryon Therapeutics NV EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.32 million.
Does Vivoryon Therapeutics NV (VVY) pay dividends?
No. Vivoryon Therapeutics NV does not pay a dividend.
When is Vivoryon Therapeutics NV (VVY) next earnings report?
Vivoryon Therapeutics NV is expected to release its next earnings report on June 30, 2026.
What is Vivoryon Therapeutics NV (VVY) beta (volatility) score?
Vivoryon Therapeutics NV has a beta of 1.448, suggesting it is more volatile than the market.
